The third panel discussion will explore the timely and evolving impact of AI in drug discovery. The panel will feature diverse perspectives from leaders across the ecosystem – including a major pharmaceutical company, an early-stage biotech, or a venture investor.
The following experts will participate:
- Kinga Matula, CEO, QurieGen
- Pavlina Koutecka, Senior scientific analyst, i&i Biotech Fund
- Jakub Lombersky, Director, ML Engineering, Intelligent Automation Engineering, MSD
- Stepanka Havlikova, Senior Associate, Dentons
Panel moderator: Chris Tame, Founder and CEO, Ternary Therapeutics
For whole profiles see the „Our speakers“ section.